BioCentury | Oct 24, 2016
Product Development

A new BEAT for AML

With the first collaborative, multidrug trial in a blood cancer, The Leukemia & Lymphoma Society aims to dramatically alter the 40-year-old diagnosis and treatment paradigm in first-line acute myelogenous leukemia, and to create a virtuous...
BioCentury | Jul 13, 2015
Emerging Company Profile

Monitoring rejections

...practice can also catch subclinical acute rejection. But biopsies are invasive and can cost $3,000-$9,000. Transplant Genomics...
...The laboratory-developed test (LDT) measures the expression of more than 100 genes in peripheral blood. Transplant Genomics...
...signature by screening blood samples from transplant recipients that had corresponding biopsy results. In May, Transplant Genomics'...
BioCentury | May 1, 2015
Company News

Management tracks

...Garen CBO. Garen was assistant VP of corporate development at Actavis plc (NYSE:ACT). Diagnostics play Transplant Genomics Inc....
BioCentury | Aug 11, 2014
Company News

Northwestern University, Scripps Research Institute, Transplant Genomics deal

...The Scripps Research Institute and Northwestern University granted Transplant Genomics exclusive rights to develop and commercialize genomics-based...
...liver transplant status. Transplant Genomics said the tests detect genomic biomarkers of transplant status from blood. Transplant Genomics...
...for details. Northwestern University , Evanston, Ill. The Scripps Research Institute , La Jolla, Calif. Transplant Genomics Inc....
Items per page:
1 - 4 of 4
BioCentury | Oct 24, 2016
Product Development

A new BEAT for AML

With the first collaborative, multidrug trial in a blood cancer, The Leukemia & Lymphoma Society aims to dramatically alter the 40-year-old diagnosis and treatment paradigm in first-line acute myelogenous leukemia, and to create a virtuous...
BioCentury | Jul 13, 2015
Emerging Company Profile

Monitoring rejections

...practice can also catch subclinical acute rejection. But biopsies are invasive and can cost $3,000-$9,000. Transplant Genomics...
...The laboratory-developed test (LDT) measures the expression of more than 100 genes in peripheral blood. Transplant Genomics...
...signature by screening blood samples from transplant recipients that had corresponding biopsy results. In May, Transplant Genomics'...
BioCentury | May 1, 2015
Company News

Management tracks

...Garen CBO. Garen was assistant VP of corporate development at Actavis plc (NYSE:ACT). Diagnostics play Transplant Genomics Inc....
BioCentury | Aug 11, 2014
Company News

Northwestern University, Scripps Research Institute, Transplant Genomics deal

...The Scripps Research Institute and Northwestern University granted Transplant Genomics exclusive rights to develop and commercialize genomics-based...
...liver transplant status. Transplant Genomics said the tests detect genomic biomarkers of transplant status from blood. Transplant Genomics...
...for details. Northwestern University , Evanston, Ill. The Scripps Research Institute , La Jolla, Calif. Transplant Genomics Inc....
Items per page:
1 - 4 of 4